These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36163427)

  • 1. Development and validation of a predictive model to guide the use of plerixafor in pediatric population.
    Sebastien B; Cheverton P; Magnin C; Aouni J; Castan R
    Bone Marrow Transplant; 2022 Dec; 57(12):1827-1832. PubMed ID: 36163427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
    Holmberg LA; Linenberger M; Connelly-Smith L
    Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
    Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
    Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.
    Lefrère F; Mauge L; Réa D; Ribeil JA; Dal Cortivo L; Brignier AC; Aoun C; Larghéro J; Cavazzana-Calvo M; Micléa JM
    Transfusion; 2013 Mar; 53(3):564-9. PubMed ID: 22725259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a reduced dose of plerixafor in combination with granulocyte colony-stimulating factor in healthy haploidentical stem cell donors.
    Kurnikova E; Trakhtman P; Balashov D; Garloeva J; Kumukova I; Khismatullina R; Pershin D; Shelikhova L; Novichkova G; Maschan A
    Vox Sang; 2022 Jun; 117(6):853-861. PubMed ID: 35332550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
    Hübel K; Fresen MM; Salwender H; Basara N; Beier R; Theurich S; Christopeit M; Bogner C; Galm O; Hartwig R; Heits F; Lordick F; Rösler W; Wehler D; Zander AR; Albert MH; Dressler S; Ebinger M; Frickhofen N; Hertenstein B; Kiehl M; Liebler S; von Lilienfeld-Toal M; Weidmann E; Weigelt C; Lange F; Kröger N
    Bone Marrow Transplant; 2011 Aug; 46(8):1045-52. PubMed ID: 20972470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
    Yang C; Dehghani M; Hopman W; Bhella S
    J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
    Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
    Karres D; Ali S; van Hennik PB; Straus S; Josephson F; Thole G; Glerum PJ; Herberts C; Babae N; Herold R; Papadouli I; Pignatti F
    Oncologist; 2020 Jun; 25(6):e976-e981. PubMed ID: 32154610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost.
    Chen KY; Bucci TG; Shaw JR; Alexander MD; Grgic T; Riches M; Ptachcinski JR
    Transfus Apher Sci; 2022 Apr; 61(2):103303. PubMed ID: 34801430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of mobilization regimen on multiday collection of peripheral blood CD34+ cells by large volume leukapheresis.
    Siddiqui I; Shmookler A; Biller E; Hardy T; Hartage R; Losos M; Chen J
    Transfusion; 2022 Apr; 62(4):857-862. PubMed ID: 35211978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
    Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
    Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].
    Chen J; Yuan LL; Zhang X; Qiao JL; Yin QX; Zhang YM; Yang XL; Cao XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):286-291. PubMed ID: 35123641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
    Costa LJ; Alexander ET; Hogan KR; Schaub C; Fouts TV; Stuart RK
    Bone Marrow Transplant; 2011 Jan; 46(1):64-9. PubMed ID: 20383210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of plerixafor in poorly mobilized allogeneic stem cell donors.
    Zhuang L; Lauro D; Wang S; Yuan S
    J Clin Apher; 2022 Aug; 37(4):388-394. PubMed ID: 35633513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An innovation in stem cell harvesting: Heparin use.
    Gul HG; Erkurt MA; Sarici A; Kuku I; Kaya E; Berber I; Merter M; Bicim S; Ozgul M
    Transfus Apher Sci; 2021 Oct; 60(5):103240. PubMed ID: 34404617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
    Ishii A; Jo T; Arai Y; Oshima S; Kanda J; Kitawaki T; Matsui K; Niwa N; Nakagawa Y; Takaori-Kondo A; Nagao M
    Cytotherapy; 2022 Jan; 24(1):49-58. PubMed ID: 34654641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.